HIA
ALNY icon

HFM Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

HFM Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$904 Buy
3
+2
+200% +$603 ﹤0.01% 773
2026
Q1 		$331 Sell
1
-9
-90% -$3.06K ﹤0.01% 828
2025
Q4 		$3.98K Buy
10
+9
+900% +$3.98K ﹤0.01% 209
2025
Q3 		$456 Sell
1
-2
-67% -$814 ﹤0.01% 704
2025
Q2 		$978 Buy
3
+2
+200% +$553 ﹤0.01% 371
2025
Q1 		$271 Buy
+1
New +$257 ﹤0.01% 516

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HFM Investment Advisors's ALNY Position: Q2 2026 in Review

HFM Investment Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 200% in Q2 2026, buying an estimated $603 and bringing the position to 3 shares worth $904. The position accounts for ﹤0.01% of the portfolio, ranked #773.

HFM Investment Advisors first reported a position in ALNY in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.98K in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • HFM Investment Advisors held 3 shares of Alnylam Pharmaceuticals worth $904 as of Q2 2026.
  • HFM Investment Advisors bought 2 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $603.
  • Alnylam Pharmaceuticals made up ﹤0.01% of HFM Investment Advisors's portfolio in Q2 2026, its #773 holding.
  • HFM Investment Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • HFM Investment Advisors's Alnylam Pharmaceuticals position peaked at $3.98K in Q4 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on HFM Investment Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.